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Many therapeutic strategies aimed at relieving symptoms of Parkinson’s disease (PD) are
currently used for treatment of this disease. With a hallmark of progressive degeneration
of dopaminergic neurons, the absence of properly operational dopaminergic circuitry
becomes a therapeutic target. Following diagnosis, dopamine replacement can be given
in the form of L-DOPA (L-3,4-dihydroxyphenylalanine). Even though it is recognized
as standard of care, this treatment strategy does not prevent the affected neurons
from degenerating. Therefore, studies have been performed using gene therapy (GT)
to make dopamine (DA) available from within the brain using an artificial DA circuitry.
One approach is to administer a GT aimed at delivering the key enzymes for DA
synthesis using a lentiviral vector system (Palfi et al., 2014). A similar approach has
been investigated with adeno-associated virus (AAV) expressing aromatic L-amino
acid decarboxylase, tyrosine hydroxylase, and GTP-cyclohydrolase I (Bankiewicz et al.,
2000), which are downregulated in PD. Another GT approach to mitigate symptoms
of PD used AAV-mediated delivery of GAD-67 (glutamate decarboxylase) (Kaplitt
et al., 2007). This approach mimics the inhibitory effect of DA neurons on their
targets, in reducing motor abnormalities. Finally, disease modifying strategies have
been undertaken using neurotrophic factors such as neurturin (NTN) (Marks et al.,
2008; Bartus et al., 2013a) or are ongoing with the closely related Glial cell line-
derived neurotrophic factor. Those approaches are aiming at rescuing the degenerating
neurons. All of the above mentioned strategies have their own merits, but also some
disadvantages. So far, none of clinical applied GT studies has resulted in significant
clinical benefit, although some clinical studies are ongoing and results are expected
over the next few years.
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INTRODUCTION
Gene therapy has shown encouraging results in preclinical models for numerous indications,
which has led to a proliferation of clinical trials. For instance in the eye, where mutations in the
RPE65 gene are the cause of inherited retinal dystrophy, gene therapy was used to introduce the
RPE65 gene (Bennett et al., 2016), leading to a reversal in blindness in patients. In addition to
the eye, the brain is an attractive organ for gene therapy and clinical trials in the central nervous
system (CNS) are also emerging. With regards to delivery for a gene therapeutic approach, there
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are generally two options, local administration or systemic
administration though intravenous injection or cerebrospinal
fluid (CSF). It is well recognized that efficient DNA delivery
is one of the critical obstacles in CNS gene therapy to
eventually obtaining clinical benefit. The blood brain barrier
(BBB) shields the brain from systemic delivery, and gene
therapy products have not proven to efficiently cross the
BBB in several animal models, with the exclusion of AAV-
9 that is able to cross the BBB to a certain extent (Foust
et al., 2008, 2009). Even though this AAV-9-mediated peripheral
approach is very promising for the treatment of CNS diseases
that affect the whole CNS, the transduction pattern following
intravenous delivery to the brain does not specifically transduce
the target structures for Parkinson’s disease (PD). Local delivery
of a therapeutic gene may result in meaningful clinical
results and has been the preferred option in clinical studies
for PD.
The option to apply a targeted local delivery makes PD a
good candidate to test advanced therapies like GT as the affected
neurons are located in a well described, relatively small nucleus,
the substantia nigra (SN). Besides the most prevalent affected
hallmark SN structure, many brainstem, limbic, and midbrain
neurons are also subject to degeneration. Still, the hallmark
of PD is the loss of dopaminergic neurons of the SN, which
leads to alterations in the activity of brain networks that control
movement (Obeso et al., 2000; Braak et al., 2003; Wichmann
and DeLong, 2003). With an uncertain etiology for dopaminergic
loss, several gene therapeutic strategies have been undertaken
that have led to clinical studies (for an overview, see Table 1).
To reach the SN, direct injections into the location can be
performed (Bartus et al., 2013a), or indirect targeting using
neuroanatomical interpretation of known connections within the
brain. For instance, neurons projecting from the putamen to
or from the SN can be used to reach the SN (see Figure 1).
Based on this assumption secreted molecules like GDNF or
neurturin (NTN) can be delivered to the SN by transducing
the putamen (Kells et al., 2012; Bartus et al., 2013b). This has
additional merit as the nigrostriatal neurons are the neurons
that degenerate, and, irrespectively of the disease state, the
neurons that are projecting from the putamen to the SN remain
intact and thus can be used (Kells et al., 2010; Ciesielska et al.,
2011).
Moreover, alternative delivery strategies can also be
undertaken using enhanced retrograde characteristics of
certain vectors. For instance, the Kobayashi laboratory has
developed an alternatively pseudotyped lentiviral vector that is
highly efficient in transducing neurons in a retrograde manner
(Hirano et al., 2013; Kato et al., 2014). By a change in the
envelope of the recombinant virus, the directional transduction
is evolved into a retrograde manner. This can have several
implications for reaching certain areas of the brain, but also for a
possible treatment of for instance motor neuron diseases (Hirano
et al., 2013). These studies are very promising for future clinical
application.
An alternative target pathway for PD, the GABAergic (gama-
aminobutyric acid) pathway, which is disrupted in PD, can be
used. This pathway is especially affected in the subthalamic
nucleus (STN). The depletion of DA and associated disturbances
in GABA circuitry also affect the thalamus, a center for motor and
cognitive control. Inhibition of the GABAergic pathway leads to
overstimulation of thalamic pathways, a process that contributes
to typical PD symptoms. The STN has served as a target for GT
under the assumption that this would permit a GT approach to
influence the GABAergic pathways (see Figure 2) (Kaplitt et al.,
2007).
Several approaches have progressed to be tried in the clinic.
Results are available from attempts to deliver GAD to the STN
using AAV aiming to restore GABAergic balance in that area.
Another approach is aimed at supplying trophic support using
Neurteurin as a therapeutic molecule. For this, AAV-mediated
delivery to the putamen or both putamen and directly into
SN was investigated. A third approach is aiming at restoring
DA synthesis by supplying DNA encoding proteins that are
involved in the cascade of DA synthesis. Both lentival-based
and AAV-derived vector delivery systems have been used in this
approach. The lentiviral delivery approach has been used for
three proteins: aromatic L-amino acid decarboxylase (AADC),
tyrosine hydroxylase (TH), and GTP-cyclohydrolase I (GCH).
The AAV-based approach is focusing on the delivery of AADC
to compensate for the downregulation of this key enzyme
in PD.
CLINICAL STUDIES
AAV-2-GAD
Parkinson’s disease is mostly associated with degeneration loss of
dopaminergic neurons in the SN, but also of many brainstem,
limbic, and midbrain neurons, which leads to alterations
in the activity of brain networks that control movement.
Alterations leading to dysregulation of interacting inhibitory
and excitatory pathways result in a movement disorder that
is characterized by difficulty initiating movements, muscular
rigidity, and tremor (Lang and Lozano, 1998; Nutt and
Wooten, 2005). Pharmacological facilitation of dopaminergic
neurotransmission benefits most patients initially, but those with
advanced PD often develop drug-related complications, such
as dyskinesia and motor fluctuations. Following start of these
complications, direct interventions increasing dopaminergic
neurotransmission could be causing adverse effects and even
worsen dyskinesia. Hence, Kaplitt et al. (2007) explored
strategies that are not based on dopamine and therefore
might provide benefit without these side-effects. In patients
with PD, increased activity of the STN is mainly caused by
a reduction of GABAergic input from the globus pallidus
(Erlander et al., 1991; Obeso et al., 2000; Wichmann and
DeLong, 2003). Clinical studies have shown that electrical
stimulation, lesioning of the STN or infusion of GABA
resulted in a reduction of STN activity. This in its turn
could ameliorate signs of advanced PD (Hamani et al., 2004).
GABA is the major inhibitory neurotransmitter in the brain.
Glutamic acid decarboxylase (GAD) is one of the key enzymes
catalyzing synthesis of GABA. Therefore, overexpression of
GAD should lead to a decreased activity of the STN and
Frontiers in Neuroanatomy | www.frontiersin.org 2 January 2017 | Volume 10 | Article 128
fnana-10-00128 January 5, 2017 Time: 12:18 # 3
Blits and Petry PD Gene Therapy Trials
TABLE 1 | Summary of gene therapy clinical studies programs for Parkinson’s disease.
Product Highest dose
(GC total)
Volume
(µl)
Target Mode of action Sponsor Indication for efficacy in Phase I
safety studies
AAV-2-GAD 1E12 50 Subthalamic
nucleus (STN)
GABA-mediated
inhibition to affected
areas
Neurologix Modest UPDRS improvement
AAV-2-AADC 0.3E12 50-450 Putamen Replacement missing
AADC gene
Genzyme/
Voyager
Modest UPDRS improvement
Increased FluoroDOPA uptake
AAV-NTN 0.5E12 50 Putamen Trophic support Ceregene No improvement UPDRS
AAV-NTN 2.4E12 50 + 10 Putamen +
Substantia
Nigra
Trophic support Ceregene Modest UPDRS, especially in early
diagnosed patients
LV-TH-GCH-
AADC
1E8 TU∗ 50 Putamen Internal dopamine
synthesis
Oxford
Biomedica
Modest UPDRS improvement
AAV-2-GDNF 3E12 450 Putamen Trophic support UCSF/NIH Not yet disclosed
∗Titer expressed in transducing units is different and cannot be compared to that of genomic copies of AAV.
FIGURE 1 | Schematic cartoon of the brain with the schematic locations of the brain targets in a cross coronal plane (A). A schematic representation of
gene therapeutic approaches to the putamen and the substantia nigra is shown in (B). Neurons in black represent the DA neurons in the SN. The dashed lines are
illustrating the degeneration of these neurons. In green are neurons depicted that project from putamen to SN. Upon putaminal transduction, neurons that project to
the SN are able to anterogradely transport therapeutic proteins to the SN. For secreted proteins, such as neurotrophic factors, this results in depositing the possibly
therapeutic protein to the targeted SN, irrespective of the status of the degenerating SN neurons. Retrograde transduction of the SN neurons via the putamen is also
possible, but dependent on the status of the DA neurons. Therefore, injections have also been performed into the SN directly on top of intraputaminal injections.
Moreover, in the putamen, some of the rate limiting enzymes of dopamine synthesis can be delivered via a gene therapeutic approach. AADC as one of the
downregulated proteins in Parkinson’s disease (PD) has been delivered to the putamen via an adeno-associated virus (AAV) vector. Via a lentiviral vector approach,
the three enzymes that are needed in the cascade of D synthesis, TH, AADC, and GCH, have been delivered. With the delivery of these enzymes, turnover of
levodopa to dopamine should be brought to more physiologically healthy levels. SN, substantia nigra; STN, subthalamic nucleus; TH, tyrosine hydroxylase; AADC,
aromatic L-amino acid decarboxylase; TH, tyrosine hydroxylase; GCH, GTP-cyclohydrolase I.
hence less innervation of the motor circuitry (see Figure 2).
Studies in animal models indicate that AAV-GAD improves
brain function without adverse toxic events (Emborg et al.,
2007).
In an open label, non-randomized phase I study, Kaplitt et al.
(2007) administered an AAV-2-GAD construct via stereotactic
surgery without any severe side effects. In the first series of trials,
the vector was delivered unilaterally; in the following trials this
was done bilaterally with a total volume of 50 µl containing
1E12 genomic copies (GC) in total (see Table 1). Their results
show that “AAV-mediated gene transfer can be done safely in
the human brain, with no evidence of substantial toxic effects or
adverse events in the perioperative period and for at least 1 year
after treatment. Most patients have been followed up for more
than 2 years after surgery, with some for more than 3 years.
No deaths and no evidence of substantial adverse events were
reported” (Kaplitt et al., 2007).
This phase I study was not designed to assess the
effectiveness of the intervention. Nonetheless, the authors
reported encouraging clinical outcomes as determined by an
increase of 3.5 points in the Unified Parkinson’s Disease Rating
Scale (UPDRS). Substantial improvements in both the off and
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FIGURE 2 | Schematic overview of therapeutic intervention in the
subthalamic nucleus. One of the effects of a depletion of dopamine is a
decreased activation of GABAergic neurons in the STN, that in their turn have
an inhibitory effect. Synthesis of GABA is enzymatically done by GAD, using
glutamate as a substrate. Transduction of the STN to produce GAD should
lead to a restoration of GABA levels in the diseased brain, leading to less
imbalance in the GABA circuitry. GABA, gama-aminobutyric acid; STN,
subthalamic nucleus; GAD, glutamate decarboxylase.
on states were evident, beginning at 3 months after surgery and
continuing until the end of the trial. This improvement was
localized predominantly to the side of the body contralateral
to the treatment (Kaplitt et al., 2007). As most of the nerve
thalamocortical fibers decussate, these results are most likely
mediated by the treatment. Although an advantage of this
approach is that it is dopamine independent, degeneration of
dopaminergic neurons still progresses resulting in an absence of
dopaminergic circuitry.
Prosavin (LV-GCH-TH-AADC)
As an alternative to restoring the GABA balance, another
approach is expressing enzymes that improve the production
of DA itself. Presently two strategies are followed to achieve an
improved DA production. In one approach, the key enzyme for
this pathway, AADC, which is downregulated in PD patients, is
supplemented via AAV-mediated GT (see Figure 1) (Christine
et al., 2009; Mittermeyer et al., 2012). In the second approach, the
three enzymes that are involved in dopamine synthesis, including
AADC as well as TH and GCH, are delivered by a lentivirus-based
vector (Palfi et al., 2014) (see Figure 1).
To overcome the loss of DA-producing neurons, an alternative
route of dopamine production was developed and investigated
by Palfi et al. (2014). Synthesis of DA by a source unrelated
to the degenerating DA cells is feasible when the enzymes that
are needed are supplemented, e.g., via a lentiviral vector. This
approach does not depend on the survival of dopaminergic
neurons, but uses remaining striatal neurons to produce
dopamine. Retrograde transduction of diseased SN neurons
projecting to the striatum, known as the nigrostriatal pathway,
might also occur. Therefore, Palfi et al. (2014) developed
a lentiviral approach, also known as Prosavin, carrying the
three protein-encoding sequences for TH, GCH, and AADC.
The rate limiting enzyme in this cascade is TH, which uses
endogenous sources for synthesis of L-dihydroxyphenylalanine,
also called levodopa. GCH is required as cofactor for TH.
Finally, AADC converts levodopa to dopamine (Shen et al., 2000;
Hadjiconstantinou and Neff, 2008; Daubner et al., 2011).
Based on this background, a clinical study was initiated in
which PD patients received bilateral injections of Prosavin into
the putamen. Patients were dosed in three cohorts, receiving a low
[1.9E7 transducing units (TU)], mid (4E7 TU) or a high dose (1E8
TU) (see Table 1). Palfi et al. (2014) described an encouraging
safety profile with no severe adverse events. Beneficial functional
data were reported at the same time as well. In all patients,
an improvement in motor score was observed. More specific, a
significant improvement in mean UPDRS part III motor scores
off medication was recorded in all patients at 6 months [mean
score 38 (SD 9) vs. 26 (8), n = 15, p = 0.0001] and 12 months
[38 vs. 27 (8); n = 15, p = 0.0001] compared with baseline.
These data were in line with preclinical results (Azzouz et al.,
2002; Jarraya et al., 2009; Palfi et al., 2014). No patients developed
off-medication dyskinesia, whereas on-medication dyskinesia
were common and were reversed by reduction in intake of
oral dopaminergic therapies. This pattern is as expected for
delivery of an efficacious dopaminergic therapy (Marks et al.,
2008). The increased occurrence of on-medication dyskinesia in
the highest dose group might correlate with the fact that this
group had the highest dopaminergic delivery to the striatum, as
noted in nonhuman primate models of PD (Jarraya et al., 2009).
Furthermore, some of the properties of DA neurons with respect
to storage, release and re-uptake of DA are lacking in non DA
neurons. This might help explain the adverse neurological events
and the interpretation of the changes in functional imaging.
In a long term follow-up of this study the predicted disease
progression, as illustrated by a yearly decline in UPDRS part
III score (off medication) of 3–4 points (Olanow et al., 2003;
Eggers et al., 2012), was absent. Even though these data are very
encouraging, they also fall within the range of placebo controls
and hence these results should be taken with caution.
However, these data provide preliminary evidence for the
safety and potential benefit for the use of lentiviral vector-
mediated delivery of key enzymes for DA synthesis. One
conclusion of the study investigators was that they were awaiting
an improvement for the delivery and use of this vector in PD
patients before they would proceed. An improvement in the
delivery method could be permit an increase in delivered volume.
Moreover, an improvement within the expression cassette such as
codon optimization or promoter design might also be useful to
increase transgene expression.
AAV-2-AADC
With the progression of the disease status of PD, one of the
main problems is that the only drug available, Levodopa (L-
Dopa), becomes less effective. It has been observed that the
effectiveness of L-Dopa decreases over time as levels of AADC
decline (Ichinose et al., 1994; Nagatsu and Sawada, 2007). This
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has led to efforts to increase AADC expression using AAV-
mediated gene therapy. Delivering AADC to the brain could
restore the therapeutic effectiveness of levodopa and improve
dopamine function.
In one study, patients received an AAV vector encoding
AADC, delivered to the putamen using MRI-guided convection-
enhanced diffusion (CED) delivery (Christine et al., 2009).
Patients also underwent positron emission tomography (PET)
scans with the AADC-specific tracer [18F]fluoro-L-mtyrosine
(FMT) 1–10 days before surgery, at 1 and 6 months after
surgery, and annually for up to 5 years. During the first
6 months, PET imaging revealed a significant elevation in
AADC expression. This result was coupled with a good
safety profile and preliminary indications of clinical benefit
(Christine et al., 2009). Long term follow up of these patients
demonstrated that this increase of AADC was maintained over
the study period, suggesting a permanent elevation of the
expression (Mittermeyer et al., 2012). This clinical study was
not designed to monitor efficacy, however, temporal analyses
of the UPDRS scores in the ON and OFF states showed a
significant improvement in the first 12 months in all patients.
This was followed by a slow deterioration over the following
years. Unfortunately, no significant differences between the
high- and low-dose patients were reported in either the ON
or OFF score. The UPDRS showed improvement within the
first 12 months. The authors indicated that the effect on the
UPDRS was most likely due, at least partially, to a placebo
effect (Mittermeyer et al., 2012). The placebo effect has been
well documented for PD (de la Fuente-Fernandez and Stoessl,
2002). The authors are currently following up with a phase 1
study aiming for 60% transduction coverage of the putamen by
increasing the volume and the dose. (ClinicalTrials.gov Identifier:
NCT019735431).
In parallel, another study also investigated the use of AAV-
AADC for the treatment of PD. Muramatsu et al. (2010) reported
an evaluation of the safety, tolerability and potential efficacy of
AAV vector-mediated gene delivery of AADC into the putamen
of six PD patients. Most important measures were UPDRS, and
PET using a tracer for AADC. Motor score was improved with
46% in the OFF state at 6 months post-intervention, whereas PET
levels increased with more than 50% and remained high up to
96 weeks, indicative of a permanent transduction of the putamen
to express AADC. They stated in their report that these results
warrant further evaluation in a randomized phase II study.
Neurotrophic Factors
During development, naturally occurring neurotrophins are
responsible and essential for neuronal growth, differentiation,
vitality, and survival. Among the members of the neurotrophic
growth factors are GDNF and NTN. Both GDNF and NTN
are members of the transforming growth factor β superfamily
(TGF β). They act through binding of GFRa1 or GFRa2 and
subsequently signal through this GFRα-ligand complex. Together
with the tyrosine kinase receptor (cRET) a functional receptor is
formed that activates downstream signal transduction pathways
1https://clinicaltrials.gov/ct2/show/NCT01973543
(Jing et al., 1996; Cik et al., 2000). Activation of those pathways
depends on the availability of receptors in a given brain structure
and thus the biological activity depends on the availability of the
receptors. During adulthood, they retain some of the vitality and
survival functions that are shown in development. Both NTN
and GDNF are naturally occurring proteins. They have potent
neurotrophic effects on midbrain dopamine neurons, including
those originating in the SN (Lin et al., 1993; Choi-Lundberg et al.,
1998; Kirik et al., 2000). The possibility that these neurotrophic
factors could be used to slow down, halt, or even reverse the
degeneration of the DA neurons has been discussed for a long
time (Lapchak et al., 1996; Björklund et al., 1997; Olanow et al.,
2015a,b). This has, for instance, been shown in many animal
models including lesioned nonhuman primates (Kordower et al.,
2000, 2006) using neurteurin as neurotrophic factor. Beneficial
effects using GDNF as a possibly therapeutic transgene have
been shown in many animal models as well and moreover
also been shown in aged nonhuman primates (Johnston et al.,
2009).
AAV-2-Neurteurin
CERE-120 (AAV-2-NTN) was developed with the goal of
restoring function and protecting neurons from further
degeneration. An initial study was performed infusing only
the putamen bilaterally; a second strategy involved also
infusion of the SN directly (see Figure 1). Results from the
first phase I clinical study suggest that CERE-120 can be
delivered safely to the putamen of PD patients. The safety of
the stereotactical procedure was similar to that of deep brain
stimulation (for review see Health Quality Ontario, 2005). In
a placebo-controlled study, AAV-treated patients improved
similarly to those of the control treated group, suggesting a
strong placebo effect (de la Fuente-Fernandez and Stoessl,
2002). The administration of the AAV vector and its subsequent
expression of the transgene did not result in any severe adverse
events related to the treatment. The investigators suggested,
however, that transduction profiles would improve when the
vector was administered to the SN. Both strategies of infusion,
putamen or putamen + SN, were followed by a phase II study.
Improvements in the UPDRS were observed, similar to those
of the placebo control group. Unfortunately, the results from
the efficacy data for both trials were mixed and disappointing
in that neither met the primary endpoint (UPDRS motor-off)
within the given timeframe. A positive and surprising twist
was noted by the improvement at the time points beyond
the prescribed timeframe (15–18 months vs. the prescribed
12 months). This is at least an indication that time is needed
to realize a treatment effect. Moreover, exploratory analysis
of the data suggested that earlier stage patients (i.e., within
5 years of diagnosis) responded much better clinically to the gene
therapeutic treatment than those treated after 10 or more years
post-diagnosis (Bartus, 2013). This is not surprising for a rescue
therapy approach; it is logical that the earlier the treatment
starts, the more neurons are likely to be saved. However, the
question of how quickly and when degenerating neurons are
beyond rescue in an irreversibly degenerated state remains to be
answered.
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CONCLUSION AND DISCUSSION
Successful delivery of the transgene is a key consideration for
all of the above-described studies to date. So far, only AAV-2 or
lentiviral vectors have been used. Both vector systems are capable
of transducing neurons in the CNS. The delivery itself is highly
dependent on the target structure.
The STN is compared to the putamen rather small and
thus requires less vector. In the putamen, several different
volumes have been infused, ranging from 50 to 450 µl per
side. The lowest amount of vector was used as starting
point, and from there volumes have increased. Also the
addition of a CED delivery method has increased the spread
of vector. Improvements in catheter design, using a so-
called step catheter to prevent backflow have added to the
improvement of vector delivery. For a full coverage of the
structure, these parameters have to be taken into account
for a successful delivery. Finally, with the aid of imaging
techniques, the injection can be followed under MRI-guidance.
This has a significant impact on the safety of the procedure
as certain structures can be avoided during the surgery and
the precision of the placement of the needle can be better
controlled (Richardson et al., 2011, for review, see Salegio et al.,
2012).
One of the merits of using growth factors, such as NTN
or GDNF is that the disease etiology may not be relevant.
Halting the process of degeneration is not per definition reliant
on the cause of disease. However, one needs to keep in mind
that the accumulation of for instance molecules such as alpha-
synuclein may cause the transport mechanisms to stall, hindering
delivery of trophic factors in a rodent model of alpha-synuclein
overexpression (Decressac et al., 2011). More sophisticated
studies remain to be undertaken to fully understand the transport
mechanisms in a PD diseased brain. For both GAD and AADC-
mediated therapies, the therapy is not related to the number
of surviving neurons, so patients with more advanced disease
may be helped with this type of therapy. Moreover, in contrast
to the use of GAD or Prosavin, neurotrophin therapy is a
so-called disease modifying as the aim of the therapy is to
interfere in the degeneration process. Neurons that are still
present are helped with a better neurotrophic factor balance. On
the other hand, when all remaining neurons have been affected,
the other options may be the therapy of choice. In general, for
a neuroprotective therapy, one needs the maximal number of
remaining neurons.
The strategy that comprises the use of GAD is a form of
treatment aiming at a more physiological method to set basal
ganglia motor circuitry to return to a normal state, as shown in
preclinical studies (Luo et al., 2002). Indeed, using deep brain
stimulation of the STN some improvement in the ON state
UPDRS is observed, however, the effect of the gene therapy
is much higher (Kleiner-Fisman et al., 2006). This observation
lends support to this possibility of reinstating homeostatic
physiological control.
Results from the clinical trials may at a first look seem
somewhat disappointing, but have brought the field to a state that
safe delivery of viral vectors into the brain is feasible. Expression
of a foreign (therapeutic) gene is possible and in none of the
studies, long term exposure to the transgene has led to severe
adverse events. With such a progression, delivery of the silver
bullet still seems within reach.
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